ATNM
Actinium·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ATNM
Actinium Pharmaceuticals, Inc.
A biopharmaceutical company that devloping drugs for cancer
Pharmaceutical
10/06/1997
03/26/2014
American Stock Exchange
37
12-31
Common stock
100 Park Ave., 23rd Floor, New York, NY 10017
--
Actinium Pharmaceuticals, Inc., was incorporated in Nevada on October 6, 1997. The company used to be a shell company, merging with suitable operating companies in the market. The company is now a biopharmaceutical company focused on the $54 billion market for cancer drugs. The company's most advanced product is Actimab -A, which contains the AC-225 antibody drug structure and is currently in human clinical trials in acute myeloid leukemia (AML) and Iomab-B, an antibody drug structure containing iodine 131 for use in hematopoietic stem cell transplantation. The company is currently designing and applying for a trial of hematopoietic stem cell transplantation for relapsed acute myeloid leukemia that is refractory to elderly patients. The company is using its expertise in the field of radioimmunotherapy to develop drugs to treat cancer. In addition, AC-225-based drug development relies on the patented α-particle immunotherapy technology (APIT) platform, which was developed in collaboration with Memorial Sloan Kettering Cancer Center, an indirect subsidiary of which Actinium Holdings LLC is the majority shareholder of the pharmaceutical company. APIT technology is very effective when combined with monoclonal antibodies, but relatively safe α particles emit radioisotopes, especially actinium 225 and bismuth 213, and the final drug structure is designed to specifically target and kill cancer cells while minimizing side effects. The company intends to develop different types of cancer treatment products, benefiting from cooperation with large pharmaceutical companies and direct sales of its products in the professional market.
Company Financials
EPS
ATNM has released its 2025 Q3 earnings. EPS was reported at -0.16, versus the expected -0.32, beating expectations. The chart below visualizes how ATNM has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ATNM has released its 2025 Q3 earnings report, with revenue of 90.00K, reflecting a YoY change of NaN%, and net profit of -5.13M, showing a YoY change of 55.64%. The Sankey diagram below clearly presents ATNM's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
